TissGeneSummary for ADAM2 |
Gene summary |
Basic gene information | Gene symbol | ADAM2 |
Gene name | ADAM metallopeptidase domain 2 | |
Synonyms | CRYN1|CRYN2|CT15|FTNB|PH-30b|PH30|PH30-beta | |
Cytomap | UCSC genome browser: 8p11.2 | |
Type of gene | protein-coding | |
RefGenes | NM_001278113.1, NM_001278114.1,NM_001464.4, | |
Description | cancer/testis antigen 15disintegrin and metalloproteinase domain-containing protein 2fertilin subunit beta | |
Modification date | 20141207 | |
dbXrefs | MIM : 601533 | |
HGNC : HGNC | ||
Ensembl : ENSG00000104755 | ||
HPRD : 03322 | ||
Vega : OTTHUMG00000164041 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_ADAM2 | |
BioGPS: 2515 | ||
Pathway | NCI Pathway Interaction Database: ADAM2 | |
KEGG: ADAM2 | ||
REACTOME: ADAM2 | ||
Pathway Commons: ADAM2 | ||
Context | iHOP: ADAM2 | |
ligand binding site mutation search in PubMed: ADAM2 | ||
UCL Cancer Institute: ADAM2 | ||
Assigned class in TissGDB* | A | |
Included tissue-specific gene expression resources | HPA,TiGER,GTExHPA,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of ADAM2 | Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Atanackovic D, Blum I, Cao Y, Wenzel S, Bartels K, Faltz C, Hossfeld DK, Hegewisch-Becker S, Bokemeyer C, Leuwer R. Cancer Biol Ther. 2006 Sep;5(9):1218-25. Epub 2006 Sep 9. (pmid:16929165) go to article | |
Description by TissGene annotations | Fused withTSGene |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for ADAM2 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
KICH | 3.833813932 | 0.072169932 | 3.761644 | 1.28E-06 | 4.75E-06 |
PRAD | 3.009210624 | 0.399385624 | 2.609825 | 1.28E-09 | 1.95E-08 |
Top |
TissGene-miRNA for ADAM2 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for ADAM2 |
TissGeneSNV for ADAM2 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.P379S | SKCM | 3 |
p.S218L | SKCM | 3 |
p.P558S | SKCM | 2 |
p.S151F | SKCM | 2 |
p.S364L | SKCM | 2 |
p.E229K | SKCM | 2 |
p.G293E | SKCM | 2 |
p.D453N | SKCM | 2 |
p.L691* | LUAD | 1 |
p.L258I | UCEC | 1 |
p.G116A | BLCA | 1 |
p.P688L | LUAD | 1 |
p.R34Q | STAD | 1 |
p.C616F | LUAD | 1 |
p.G10R | SKCM | 1 |
p.D583E | HNSC | 1 |
p.R71* | HNSC | 1 |
p.S226F | LIHC | 1 |
p.S275* | LUSC | 1 |
p.K552Q | CESC | 1 |
p.G569E | SKCM | 1 |
p.P129T | LGG | 1 |
p.G543* | STAD | 1 |
p.S43L | SKCM | 1 |
p.E576K | SKCM | 1 |
p.Q712X | SKCM | 1 |
p.F690Y | SKCM | 1 |
p.G543R | SARC | 1 |
p.H68Q | HNSC | 1 |
p.D724N | BLCA | 1 |
p.V4I | COAD | 1 |
p.V295F | LUAD | 1 |
p.I483F | SKCM | 1 |
p.C331X | THYM | 1 |
p.S306L | SKCM | 1 |
p.G430R | LUAD | 1 |
p.C433* | LUAD | 1 |
p.H193Y | LUSC | 1 |
p.I409F | LUAD | 1 |
p.Q495K | ESCA | 1 |
p.S104F | SKCM | 1 |
p.R713K | SKCM | 1 |
p.N235T | UCEC | 1 |
p.T618N | ESCA | 1 |
p.V265M | LUAD | 1 |
p.C92R | LUAD | 1 |
p.S169N | SKCM | 1 |
p.H372Y | SKCM | 1 |
p.I127V | LIHC | 1 |
p.I51F | KIRP | 1 |
p.N90I | ESCA | 1 |
p.F381L | HNSC | 1 |
p.D378Y | UCEC | 1 |
p.D623Y | UCEC | 1 |
p.G531E | SKCM | 1 |
p.S440* | PRAD | 1 |
p.K518N | LUAD | 1 |
p.G126R | SKCM | 1 |
p.E273* | BLCA | 1 |
p.P455S | LUAD | 1 |
p.V117A | STAD | 1 |
p.Y94* | LUAD | 1 |
p.S448Y | PRAD | 1 |
p.N603D | UCEC | 1 |
p.R605K | SKCM | 1 |
p.F91I | SKCM | 1 |
p.E181K | SKCM | 1 |
p.C542R | LUAD | 1 |
p.W482* | SKCM | 1 |
p.G79E | SKCM | 1 |
p.K683* | BLCA | 1 |
p.S346C | LUSC | 1 |
p.S133L | SKCM | 1 |
p.I485L | LUSC | 1 |
p.K328T | COAD | 1 |
p.Q712* | SKCM | 1 |
p.E357K | SKCM | 1 |
p.S584I | PCPG | 1 |
p.V170I | GBM | 1 |
p.G424V | OV | 1 |
p.S303I | BRCA | 1 |
p.P733A | LUSC | 1 |
p.L408R | STAD | 1 |
p.S124T | BLCA | 1 |
p.D619N | SKCM | 1 |
p.K586N | HNSC | 1 |
p.R559* | LUSC | 1 |
p.N480K | KIRC | 1 |
p.R376C | PAAD | 1 |
p.G735E | SARC | 1 |
p.G659D | READ | 1 |
p.H570Y | COAD | 1 |
p.V309I | LUAD | 1 |
p.S226F | SKCM | 1 |
p.N327S | LGG | 1 |
p.Q604E | BLCA | 1 |
p.S43L | LUSC | 1 |
p.H361Q | SKCM | 1 |
p.G241R | SKCM | 1 |
p.S364* | BLCA | 1 |
p.R376C | HNSC | 1 |
p.R559K | SKCM | 1 |
p.S568C | LUSC | 1 |
p.Q585H | STAD | 1 |
p.K144Q | READ | 1 |
p.P667S | PAAD | 1 |
p.Q647* | SKCM | 1 |
p.G592E | SKCM | 1 |
p.A665T | SKCM | 1 |
p.Y291C | STAD | 1 |
p.H581Y | SKCM | 1 |
p.G543A | BLCA | 1 |
p.L225V | HNSC | 1 |
p.V200F | PAAD | 1 |
p.Q647X | SKCM | 1 |
p.C452X | SKCM | 1 |
p.P299L | SKCM | 1 |
p.S76G | HNSC | 1 |
p.G210E | SKCM | 1 |
p.V259F | BLCA | 1 |
p.S597L | SKCM | 1 |
p.S609F | PCPG | 1 |
p.R15W | COAD | 1 |
p.E242K | READ | 1 |
p.N122I | LIHC | 1 |
p.A385V | COAD | 1 |
p.G424C | LUAD | 1 |
p.C400F | LUAD | 1 |
p.I656T | OV | 1 |
p.W482X | SKCM | 1 |
p.C572Y | STAD | 1 |
p.D264N | LUSC | 1 |
p.G10W | DLBC | 1 |
p.R3H | LIHC | 1 |
p.C414S | LUAD | 1 |
p.F695L | UCEC | 1 |
p.K236N | SKCM | 1 |
p.Q174H | SKCM | 1 |
p.S682F | SKCM | 1 |
p.V4I | HNSC | 1 |
p.L230F | SKCM | 1 |
p.G100C | UCEC | 1 |
p.S368F | SKCM | 1 |
p.V4I | LGG | 1 |
p.S440T | HNSC | 1 |
p.I321N | ACC | 1 |
p.C452* | SKCM | 1 |
p.D724N | ESCA | 1 |
p.P667L | KIRC | 1 |
p.N468H | UCEC | 1 |
p.Q283K | LIHC | 1 |
p.G543X | STAD | 1 |
p.S610T | LIHC | 1 |
p.N678K | THYM | 1 |
p.R115G | KIRC | 1 |
p.V143G | HNSC | 1 |
p.S594F | BLCA | 1 |
p.G279S | LUAD | 1 |
p.R674H | KIRP | 1 |
p.N64H | READ | 1 |
p.T240A | LUAD | 1 |
p.K683N | BLCA | 1 |
p.D724N | SKCM | 1 |
p.C644* | LUSC | 1 |
p.D288N | STAD | 1 |
p.G13V | LUAD | 1 |
p.G10R | ESCA | 1 |
p.A385S | GBM | 1 |
p.Q556H | HNSC | 1 |
p.K204E | SKCM | 1 |
Top |
TissGeneCNV for ADAM2 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for ADAM2 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Chimerdb3.0 | FusionScan | BRCA | TCGA-E2-A15A-01A | KAT6A-ADAM2 | In-Frame | chr8:41905895 | chr8:39624770 |
Chimerdb3.0 | FusionScan | BRCA | TCGA-E2-A15A-01A | KAT6A-ADAM2 | Out-of-Frame | chr8:41905895 | chr8:39627094 |
Chimerdb3.0 | FusionScan | BRCA | TCGA-E2-A15A-01A | KAT6A-ADAM2 | In-Frame | chr8:41905895 | chr8:39646259 |
Chimerdb3.0 | FusionScan | BRCA | TCGA-E2-A15R-01A | CPT1A-ADAM2 | In-Frame | chr11:68540732 | chr8:39607263 |
Chimerdb3.0 | TopHat-Fusion | BRCA | TCGA-E2-A15A-01A | KAT6A-ADAM2 | In-Frame | chr8:41905895 | chr8:39624769 |
Chimerdb3.0 | TopHat-Fusion | BRCA | TCGA-E2-A15A-01A | KAT6A-ADAM2 | Out-of-Frame | chr8:41905895 | chr8:39627093 |
Chimerdb3.0 | TopHat-Fusion | BRCA | TCGA-E2-A15A-06A | KAT6A-ADAM2 | In-Frame | chr8:41905895 | chr8:39624769 |
Chimerdb3.0 | TopHat-Fusion | BRCA | TCGA-E2-A15A-06A | KAT6A-ADAM2 | Out-of-Frame | chr8:41905895 | chr8:39627093 |
Chimerdb3.0 | TopHat-Fusion | BRCA | TCGA-AR-A256-01A | ADAM2-MAVS | In-Frame | chr8:39626883 | chr20:3835387 |
Chimerdb3.0 | TopHat-Fusion | BRCA | TCGA-AR-A256-01A | ADAM2-MAVS | Out-of-Frame | chr8:39626949 | chr20:3835387 |
TCGAfusionPortal | PRADA | BRCA | TCGA-E2-A15A-01A | KAT6A-ADAM2 | Out-of-frame | Chr8:41905896 | Chr8:39627094 |
TCGAfusionPortal | PRADA | BRCA | TCGA-E2-A15R-01A | CPT1A-ADAM2 | In-frame | Chr11:68540733 | Chr8:39607263 |
TCGAfusionPortal | PRADA | LUAD | TCGA-44-8117-01A | HIRA-ADAM2 | Out-of-frame | Chr22:19393309 | Chr8:39627094 |
TCGAfusionPortal | PRADA | LUAD | TCGA-86-A4D0-01A | ADAM2-MTMR2 | Out-of-frame | Chr8:39603991 | Chr11:95598840 |
Top |
TissGeneNet for ADAM2 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for ADAM2 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for ADAM2 |
TissGeneDrug for ADAM2 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for ADAM2 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0153594 | Malignant neoplasm of testis | 1 | BeFree |
umls:C0740457 | Malignant neoplasm of kidney | 1 | BeFree |
umls:C1378703 | Renal carcinoma | 1 | BeFree |